Table 2

Association between NOTCH1/SF3B1 gene mutation status and clinical characteristics of the LRF CLL4 patients

VariableNOTCH1 mutated cases (all PEST terminating mutations)
SF3B1 mutated cases (previously shown as somatic in CLL)
OR95% CISEPn = *OR95% CISEPn = *
Age at diagnosis 1.04 0.99-1.07 0.02 .06 466 1.01 0.98-1.04 0.02 .46 437 
Sex 0.66 0.31-1.41 0.26 .29 466 0.79 0.44-1.43 0.30 .43 437 
Binet stage (A, B, or C) 0.85 0.56-1.29 0.18 .45 466 1.23 0.86-1.75 0.18 .26 437 
CD38 positive 5.03 2.32-10.90 1.98 < .001 382 2.33 1.28-4.25 0.71 .005 353 
ZAP70 positive 2.92 1.32-6.42 1.17 .007 350 1.40 0.78-2.53 0.42 .26 328 
IGHV unmutated 2.91 1.24-6.80 0.15 .014 384 1.72 0.93-3.19 0.18 .09 359 
TP53 del/mut 1.31 0.44-3.94 0.56 .63 440 0.71 0.21-2.45 0.63 .59 412 
del(11q) 0.60 0.24-1.46 0.27 .26 441 0.73 0.37-1.47 0.26 .38 413 
del(13q)† 0.54 0.27-1.09 0.19 .09 441 1.08 0.63-1.83 0.28 .79 413 
Tri12 3.09 1.56-6.11 1.08 .001 441 0.19 0.06-0.63 0.12 .006 413 
Response to treatment‡ 0.88 0.57-1.35 0.19 .58 441 0.95 0.67-1.36 0.18 .79 413 
LRF CLL4 treatment arm§ 0.68 0.45-1.03 0.14 .07 466 1.15 0.84-1.56 0.16 .38 437 
VariableNOTCH1 mutated cases (all PEST terminating mutations)
SF3B1 mutated cases (previously shown as somatic in CLL)
OR95% CISEPn = *OR95% CISEPn = *
Age at diagnosis 1.04 0.99-1.07 0.02 .06 466 1.01 0.98-1.04 0.02 .46 437 
Sex 0.66 0.31-1.41 0.26 .29 466 0.79 0.44-1.43 0.30 .43 437 
Binet stage (A, B, or C) 0.85 0.56-1.29 0.18 .45 466 1.23 0.86-1.75 0.18 .26 437 
CD38 positive 5.03 2.32-10.90 1.98 < .001 382 2.33 1.28-4.25 0.71 .005 353 
ZAP70 positive 2.92 1.32-6.42 1.17 .007 350 1.40 0.78-2.53 0.42 .26 328 
IGHV unmutated 2.91 1.24-6.80 0.15 .014 384 1.72 0.93-3.19 0.18 .09 359 
TP53 del/mut 1.31 0.44-3.94 0.56 .63 440 0.71 0.21-2.45 0.63 .59 412 
del(11q) 0.60 0.24-1.46 0.27 .26 441 0.73 0.37-1.47 0.26 .38 413 
del(13q)† 0.54 0.27-1.09 0.19 .09 441 1.08 0.63-1.83 0.28 .79 413 
Tri12 3.09 1.56-6.11 1.08 .001 441 0.19 0.06-0.63 0.12 .006 413 
Response to treatment‡ 0.88 0.57-1.35 0.19 .58 441 0.95 0.67-1.36 0.18 .79 413 
LRF CLL4 treatment arm§ 0.68 0.45-1.03 0.14 .07 466 1.15 0.84-1.56 0.16 .38 437 
*

Shows the number of observations included in each logistic regression analysis.

†

The presence of a 13q deletion as a sole abnormality using a standard FISH panel.

‡

Defined as response (CR/nPR, PR, NR) to any treatment.

§

Any treatment (CHL, FC, FDR). TP53 abnormalities defined by deletion and/ or mutation (del/mut).

View Large